BioVersys (SIX: BIOV)

Last close As at 28/02/2026

CHF24.40

0.60 (2.52%)

Market capitalisation

BioVersys is a multi-asset, clinical-stage biopharmaceutical company focussed on the development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant bacteria.

Latest Insights

View More

Healthcare | podcast

Bull, Bear & Beyond – BioVersys: executive interview

Healthcare | Initiation

BioVersys — Poised to unlock value in critical AMR

Healthcare | edison tv

BioVersys – executive interview

Healthcare | SIX — initiation

BioVersys — Targeting resistant and threatening indications

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Dr. Marc Gitzinger

    CEO & Founder

  • Hernan Levett

    CFO